drugset / Trial / NCT04073134

The CHORAL Flow Study

NCT04073134

Phase 4 Terminated 12 enrolled Imperial College London
RandomizedParallel-groupQuadruple-blindTreatment

Summary

CHORAL Flow is a randomised, double blinded, placebo-controlled trial of the effects of evolocumab on coronary flow at 12 weeks.

Timeline

Start
2019-09-11
Primary completion
2022-03-27
Completion
2022-05-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Evolocumab Monoclonal antibody 140 mg Subcutaneous